Benzinga | Apr 9, 2021 07:22AM EDT

HC Wainwright & Co. Maintains Neutral on KemPharm, Lowers Price Target to $10

HC Wainwright & Co. analyst Oren Livnat maintains KemPharm (NASDAQ:KMPH) with a Neutral and lowers the price target from $12 to $10.